Ann: Quarterly Activities/Appendix 4C Cash Flow Report, page-4

Silva - MDC is not only far from drug registration but also haven't completed clinical trials...cash in bank doesn't mean much if mngt spents it on lifestyle...with current capital market conditions in US, MDC heading into some serious financial constraints without successful CR.. Company is not transparent on its cost structure- how many employees?? company calls itself drug delivery platform yet hasn't been able to monetise nanocelle so far and expecting significant CR for something that is not even core part of their business model...red alerts all over the place..
DYOR imo